Abstract P212: Sphingolipid De Novo Pathway is a Novel Regulator of Blood Pressure Homeostasis

Anna Cantalupo,Yi Zhang,Xian-Cheng Jiang,Annarita Di Lorenzo
DOI: https://doi.org/10.1161/hyp.68.suppl_1.p212
IF: 9.8968
2016-01-01
Hypertension
Abstract:Background and objectives: Sphingolipids, particularly sphingosine 1-phosphate (S1P), play an important role in the cardiovascular homeostasis. Recently, we revealed that endothelial de novo biosynthesis of sphingolipids is very important to control vascular functions and blood pressure. We discovered that in blood vessels, particularly in endothelial cells, Nogo-B, a membrane protein of the endoplasmic reticulum, inhibits serine palmitoyltransferase (SPT), the first and rate-limiting enzyme of de novo production of sphingolipids, to impact vascular tone and blood pressure. Indeed, mice lacking Nogo-B are protected from angiotensin II-induced hypertension, and pharmacological inhibition of SPT by myriocin reinstates high blood pressure in absence of Nogo-B, suggesting that the upregulation of SPT activity exerts anti-hypertensive functions. Thus, the goal of this study is to investigate the role of SPT in vascular functions and blood pressure regulation by using novel genetic mouse models. Methods: The SBP was evaluated in 14 weeks old mice heterozygous for Sptlc2 ( Sptlc2 +/- ) or lacking Sptlc2 specifically in endothelial cells (ECKO Sptlc2 ) and smooth muscle cells (SMCKO Sptlc2 ) by using tail-cuff system. Vascular reactivity of isolated mesenteric arteries was assessed ex-vivo by using the pressure myograph system. Results: Sptlc2 +/- , ECKO Sptlc2 and SMCKO Sptlc2 mice were hypertensive compared to their respective controls ( Sptlc2 +/- 128.9±2.6 vs. WT 112.1±2.6 mmHg; ECKO Sptlc2 125.5±1.8, SMCKO Sptlc2 127.2±0.6 vs. Sptlc2 f/f 106±0.84 mmHg) and developed endothelial dysfunction as shown by the impaired vasodilation in response to acetylcholine (EC 50 Sptlc2 +/- 1.48x10 -6 M vs. WT 4.46x10 -7 M; Emax ECKO Sptlc2 73.2±3.3% vs. Sptlc2 f/f 95.3±1.1%), as well as to flow (Emax: Sptlc2 +/- 23.3±1.4 μm vs. WT 42.9±4.4 μm; ECKO Sptlc2 19.9±0.9 μm vs. Sptlc2 f/f 41.3±3.1 μm). Conclusion: This study demonstrates the important role of SPT, thus the de novo production of sphingolipids, in controlling blood flow and pressure homeostasis, and provides the ground for the development of alternative therapeutic strategies to manage high blood pressure.
What problem does this paper attempt to address?